Loading…
Mukka Proteins (MUKKA)₹27.81+0.72%Animal Feed
In the Jun 2026 quarter (consolidated), Mukka Proteins reported sales of ₹489 Cr, up 186.5% from Jun 2025, and net profit of ₹18.93 Cr, up 851.3% year on year. For the year to Mar 2026, sales were ₹1,446 Cr and net profit ₹56.79 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 331 | 515 | 256 | 172 | 149 | 302 | 381 | 171 | 244 | 652 | 380 | 489 |
| Expenses | 293 | 497 | 223 | 159 | 140 | 261 | 351 | 157 | 223 | 607 | 346 | 442 |
| Operating Profit | 38.10 | 19.05 | 32.08 | 14.03 | 10.03 | 41.06 | 29.05 | 14.02 | 20.05 | 45.08 | 34.05 | 47.10 |
| OPM % | 10.9% | 3.6% | 13.0% | 8.0% | 6.0% | 14.0% | 8.0% | 8.0% | 8.0% | 7.0% | 9.0% | 10.0% |
| Other Income | 5.99 | 7.98 | 4.99 | 2.99 | 3.99 | 5.99 | 3.99 | 2.99 | 5.99 | 7.99 | 14.98 | 1.99 |
| Interest | 5.99 | 5.98 | 6.98 | 7.99 | 8.98 | 10.98 | 9.99 | 10.98 | 12.97 | 14.97 | 14.98 | 15.98 |
| Depreciation | 2.99 | 2.99 | 2.99 | 3.01 | 4.01 | 3.99 | 2.99 | 2.99 | 3.99 | 4.01 | 4.99 | 4.99 |
| Profit before tax | 35.13 | 17.06 | 27.10 | 6.01 | 1.01 | 33.09 | 20.05 | 2.01 | 9.03 | 35.09 | 29.09 | 27.09 |
| Tax % | 18.0% | 31.1% | −8.0% | 5.0% | −40.0% | 19.1% | 30.1% | 33.1% | 26.1% | 21.1% | 26.1% | 32.1% |
| Net Profit | 28.89 | 11.96 | 28.88 | 4.98 | 0.99 | 26.90 | 13.96 | 1.99 | 6.97 | 26.89 | 20.92 | 18.93 |
| EPS (Rs) | 1.29 | 0.49 | 0.90 | 0.15 | 0.08 | 0.89 | 0.46 | 0.06 | 0.21 | 0.80 | 0.70 | 0.64 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 408 | 548 | 602 | 767 | 1,173 | 1,376 | 1,003 | 1,446 | 1,766 |
| Expenses | 384 | 524 | 580 | 721 | 1,088 | 1,270 | 910 | 1,331 | 1,617 |
| Operating Profit | 23.04 | 24.06 | 22.04 | 48.07 | 86.14 | 105 | 95.15 | 115 | 146 |
| OPM % | 6.0% | 4.3% | 3.6% | 6.0% | 7.0% | 8.0% | 9.0% | 8.0% | 8.3% |
| Other Income | 1.99 | 7.98 | 9.98 | 6.99 | 7.99 | 18.97 | 15.97 | 30.96 | 30.95 |
| Interest | 3.99 | 6.98 | 7.98 | 9.98 | 15.97 | 24.95 | 36.95 | 53.92 | 58.90 |
| Depreciation | 1.99 | 4.99 | 7.99 | 8.99 | 11.99 | 11.99 | 13.99 | 16.99 | 17.98 |
| Profit before tax | 19.06 | 20.07 | 15.04 | 36.10 | 66.23 | 87.32 | 60.14 | 75.24 | 100 |
| Tax % | 27.1% | 31.0% | 29.1% | 28.1% | 28.1% | 15.1% | 20.1% | 24.1% | — |
| Exceptional items | 0.00 | 1.99 | 2.99 | 0.99 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 13.95 | 13.94 | 10.97 | 25.92 | 47.80 | 73.71 | 47.86 | 56.79 | 73.71 |
| EPS (Rs) | — | — | — | 1.11 | 2.01 | 2.33 | 1.56 | 1.75 | 2.35 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.02 | 6.01 | 6.02 | 21.97 | 21.96 | 29.92 | 29.96 | 29.97 |
| Reserves | 38.12 | 51.09 | 61.21 | 75.90 | 126 | 365 | 410 | 469 |
| Borrowings | 82.83 | 142 | 159 | 174 | 261 | 364 | 452 | 777 |
| Other Liabilities | 73.64 | 94.55 | 128 | 118 | 165 | 178 | 182 | 341 |
| Total Liabilities | 201 | 292 | 354 | 391 | 573 | 938 | 1,073 | 1,617 |
| Fixed Assets | 49.08 | 78.16 | 79.18 | 83.10 | 85.12 | 85.17 | 94.22 | 194 |
| CWIP | 0.00 | 2.01 | 4.01 | 0.00 | 0.00 | 0.00 | 9.02 | 31.08 |
| Investments | 7.99 | 3.99 | 11.97 | 20.95 | 20.96 | 30.95 | 36.92 | 55.90 |
| Other Assets | 144 | 208 | 259 | 288 | 467 | 822 | 934 | 1,337 |
| Inventories | 89.99 | 115 | 150 | 165 | 230 | 423 | 564 | 858 |
| Trade receivables | 27.96 | 34.95 | 47.92 | 60.88 | 113 | 185 | 200 | 182 |
| Cash & equivalents | 1.01 | 2.01 | 4.01 | 14.03 | 29.09 | 127 | 42.12 | 60.18 |
| Total Assets | 201 | 292 | 354 | 391 | 573 | 938 | 1,073 | 1,617 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −19.96 | −24.94 | 1.99 | 4.98 | −55.82 | −150 | −112 | −111 |
| Cash from investing activity | −23.02 | −28.02 | −13.99 | −11.01 | −3.01 | −48.02 | −35.01 | −146 |
| Cash from financing activity | 33.99 | 54.01 | 13.01 | 15.01 | 75.01 | 266 | 55.98 | 267 |
| Net cash flow | −9.01 | 1.01 | 2.01 | 8.01 | 15.03 | 68.11 | −91.17 | 10.01 |
| Capex | 19.05 | 36.09 | 11.04 | 7.02 | 8.03 | 16.04 | 20.05 | 121 |
| Free cash flow | −39.07 | −61.10 | −8.02 | −1.01 | −64.07 | −165 | −130 | −231 |
| CFO / OP % | −66.9% | −80.9% | 29.1% | 22.1% | −51.9% | −117.9% | −113.9% | −83.9% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor days | 25 | 23 | 29 | 29 | 35 | 49 | 72 | 46 |
| Inventory days | 95 | 89 | 106 | 95 | 89 | 136 | 266 | 267 |
| Days payable | 64 | 64 | 72 | 57 | 52 | 45 | 68 | 76 |
| Cash conversion cycle | 58 | 50 | 65 | 69 | 74 | 142 | 273 | 239 |
| Working capital days | 5 | −8 | −11 | 0 | 11 | 46 | 100 | 46 |
| ROCE % | — | 14.9% | 9.0% | 17.9% | 24.0% | 19.0% | 11.9% | 11.9% |
For the Jun 2026 quarter, Mukka Proteins reported sales of ₹489 Cr, up 186.5% year on year and net profit of ₹18.93 Cr, up 851.3% year on year. The operating margin was 10.0%.
Mukka Proteins' sales for the year to Mar 2026 were ₹1,446 Cr; over the last twelve months they were ₹1,766 Cr.
Net profit for the year to Mar 2026 was ₹56.79 Cr, and ₹73.71 Cr over the last twelve months. Earnings per share over the same trailing period were ₹2.35.
Mukka Proteins reported borrowings of ₹777 Cr at Mar 2026, against cash and equivalents of ₹60.18 Cr.
Cash from operations was −₹111 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹231 Cr.